ALEX Phase 3 trial

June 8, 2017June 8, 2017

Alecensa Doubles Time to Disease Progression in Untreated ALK+ NSCLC Patients Compared to Xalkori

News

Genentech’s Alecensa (alectinib) reduced the risk of disease progression or death by 53 percent compared to Xalkori (crizotinib) — the standard of care treatment for advanced ALK-positive non-small cell lung cancer (NSCLC) — concludes the ... Read more

April 11, 2017April 11, 2017

Genentech’s Alecensa Superior to Xalkori in Newly Diagnosed ALK+ Advanced NSCLC Patients

News

Patients with ALK-positive advanced non-small cell lung cancer (NSCLC) who receive Genentech’s Alecensa (alectinib) as first-line therapy have significantly higher progression-free survival rates compared to those treated with the standard ... Read more

October 6, 2016

Alecensa Receives FDA Breakthrough Therapy Designation for First-Line Treatment of ALK-Positive NSCLC

News

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Genentech’s anaplastic lymphoma kinase (ALK) inhibitor Alecensa (alectinib) for the treatment of adults with ALK-positive non-small cell lung ... Read more